{"DataElement":{"publicId":"3083669","version":"1","preferredName":"Neoadjuvant Therapy Administered Type","preferredDefinition":"a subdivision related to neoadjuvant therapy, treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents, being administered.","longName":"2188393v1.0:3083663v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2188393","version":"1","preferredName":"Neoadjuvant Therapy Administered","preferredDefinition":"information related to neoadjuvant therapy, treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents, being administered.","longName":"NEOADJ_TX_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2718486","version":"1","preferredName":"Neoadjuvant Therapy","preferredDefinition":"Treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents. Induction therapy is followed by additional therapy to eliminate whatever cancer remains.","longName":"C15665","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoadjuvant Therapy","conceptCode":"C15665","definition":"Therapy administered prior to the primary treatment for the purpose of making the primary treatment more effective.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"42D7D4EB-6EB9-0FF3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-03","modifiedBy":"ONEDATA","dateModified":"2008-01-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E40DA276-BE0A-601E-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-28","endDate":null,"createdBy":"SHIDED","dateCreated":"2004-09-14","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3083663","version":"1","preferredName":"Neoadjuvant Therapy Administered Type","preferredDefinition":"a subdivision of neoadjuvant therapy administered.","longName":"3083663v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Arm B - Clofarbine","valueDescription":"Arm B - Clofarbine","ValueMeaning":{"publicId":"3083664","version":"1","preferredName":"Arm B - Clofarbine","longName":"3083664","preferredDefinition":"Arm B - Clofarbine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86060C49-5DF7-0CCB-E040-BB89AD43412E","latestVersionIndicator":"Yes","beginDate":"2010-05-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86060C49-5E10-0CCB-E040-BB89AD43412E","beginDate":"2010-05-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-07","modifiedBy":"ONEDATA","dateModified":"2010-05-07","deletedIndicator":"No"},{"value":"Arm A - Daunorubicin + Cytarabine","valueDescription":"Arm A - Daunorubicin + Cytarabine","ValueMeaning":{"publicId":"3083665","version":"1","preferredName":"Arm A - Daunorubicin + Cytarabine","longName":"3083665","preferredDefinition":"Arm A - Daunorubicin + Cytarabine","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86060C49-5E1A-0CCB-E040-BB89AD43412E","latestVersionIndicator":"Yes","beginDate":"2010-05-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"86060C49-5E33-0CCB-E040-BB89AD43412E","beginDate":"2010-05-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-07","modifiedBy":"ONEDATA","dateModified":"2010-05-07","deletedIndicator":"No"},{"value":"Arm C - BR followed by Lenalidomide and Rituximab - Arm F","valueDescription":"Arm C - BR followed by Lenalidomide and Rituximab - Arm F","ValueMeaning":{"publicId":"3132441","version":"1","preferredName":"Arm C - BR followed by Lenalidomide and Rituximab - Arm F","longName":"3132441","preferredDefinition":"Arm C - BR followed by Lenalidomide and Rituximab - Arm F","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E94E22B-CE4A-4CDF-E040-BB89AD434B37","latestVersionIndicator":"Yes","beginDate":"2010-08-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-08-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E94E22B-CE63-4CDF-E040-BB89AD434B37","beginDate":"2010-08-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-08-24","modifiedBy":"ONEDATA","dateModified":"2010-08-24","deletedIndicator":"No"},{"value":"Arm B - BVR followed by Rituximab - Arm E","valueDescription":"Arm B - BVR followed by Rituximab - Arm E","ValueMeaning":{"publicId":"3132442","version":"1","preferredName":"Arm B - BVR followed by Rituximab - Arm E","longName":"3132442","preferredDefinition":"Arm B - BVR followed by Rituximab - Arm E","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E94E22B-CE6D-4CDF-E040-BB89AD434B37","latestVersionIndicator":"Yes","beginDate":"2010-08-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-08-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E94E22B-CE86-4CDF-E040-BB89AD434B37","beginDate":"2010-08-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-08-24","modifiedBy":"ONEDATA","dateModified":"2010-08-24","deletedIndicator":"No"},{"value":"Arm A - BR followed by Rituximab - Arm D","valueDescription":"Arm A - BR followed by Rituximab - Arm D","ValueMeaning":{"publicId":"3132443","version":"1","preferredName":"Arm A - BR followed by Rituximab - Arm D","longName":"3132443","preferredDefinition":"Arm A - BR followed by Rituximab - Arm D","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E94E22B-CE90-4CDF-E040-BB89AD434B37","latestVersionIndicator":"Yes","beginDate":"2010-08-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-08-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E94E22B-CEA9-4CDF-E040-BB89AD434B37","beginDate":"2010-08-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-08-24","modifiedBy":"ONEDATA","dateModified":"2010-08-24","deletedIndicator":"No"},{"value":"Arm D - BVR followed by Lenalidomide + Rituximab - Arm H","valueDescription":"Arm D - BVR followed by Lenalidomide + Rituximab - Arm H","ValueMeaning":{"publicId":"3269923","version":"1","preferredName":"Arm D - BVR followed by Lenalidomide + Rituximab - Arm H","longName":"3269923","preferredDefinition":"Arm D - BVR followed by Lenalidomide + Rituximab - Arm H","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC488515-E509-8C62-E040-BB89AD4375E1","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AC488515-E522-8C62-E040-BB89AD4375E1","beginDate":"2011-09-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-09-06","modifiedBy":"ONEDATA","dateModified":"2011-09-06","deletedIndicator":"No"},{"value":"Arm C - BR followed by Lenalidomide + Rituximab - Arm G","valueDescription":"Arm C - BR followed by Lenalidomide + Rituximab - Arm G","ValueMeaning":{"publicId":"3269924","version":"1","preferredName":"Arm C - BR followed by Lenalidomide + Rituximab - Arm G","longName":"3269924","preferredDefinition":"Arm C - BR followed by Lenalidomide + Rituximab - Arm G","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC488515-E52C-8C62-E040-BB89AD4375E1","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AC488515-E545-8C62-E040-BB89AD4375E1","beginDate":"2011-09-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-09-06","modifiedBy":"ONEDATA","dateModified":"2011-09-06","deletedIndicator":"No"},{"value":"Arm A - BR followed by Rituximab - Arm E","valueDescription":"Arm A - BR followed by Rituximab - Arm E","ValueMeaning":{"publicId":"3269925","version":"1","preferredName":"Arm A - BR followed by Rituximab - Arm E","longName":"3269925","preferredDefinition":"Arm A - BR followed by Rituximab - Arm E","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC488515-E54F-8C62-E040-BB89AD4375E1","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AC488515-E568-8C62-E040-BB89AD4375E1","beginDate":"2011-09-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-09-06","modifiedBy":"ONEDATA","dateModified":"2011-09-06","deletedIndicator":"No"},{"value":"Arm B - BVR followed by Rituximab - Arm F","valueDescription":"Arm B - BVR followed by Rituximab - Arm F","ValueMeaning":{"publicId":"3269926","version":"1","preferredName":"Arm B - BVR followed by Rituximab - Arm F","longName":"3269926","preferredDefinition":"Arm B - BVR followed by Rituximab - Arm F","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC488515-E572-8C62-E040-BB89AD4375E1","latestVersionIndicator":"Yes","beginDate":"2011-09-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-09-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AC488515-E58B-8C62-E040-BB89AD4375E1","beginDate":"2011-09-06","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-09-06","modifiedBy":"ONEDATA","dateModified":"2011-09-06","deletedIndicator":"No"},{"value":"Immunotherapy","valueDescription":"Immunotherapy","ValueMeaning":{"publicId":"2570354","version":"1","preferredName":"Immunotherapy","longName":"2570354","preferredDefinition":"(IM-yoo-no-THER-a-pee) Treatment to stimulate or restore the ability of the immune system to fight infections and other diseases. Also used to lessen side effects that may be caused by some cancer treatments.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunotherapy","conceptCode":"C15262","definition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DFDF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"41F89AF3-89B4-1889-E053-F662850A9BF2","beginDate":"2016-11-23","endDate":null,"createdBy":"PATELV","dateCreated":"2016-11-23","modifiedBy":"ONEDATA","dateModified":"2016-11-23","deletedIndicator":"No"},{"value":"Cytotoxic Chemotherapy","valueDescription":"Cytotoxic Chemotherapy","ValueMeaning":{"publicId":"4780585","version":"1","preferredName":"Cytotoxic Chemotherapy","longName":"4780585","preferredDefinition":"Anticancer drugs that kill cells, especially cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytotoxic Chemotherapy","conceptCode":"C15681","definition":"A drug therapy that is used to destroy cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1323EF80-FA3E-173F-E050-BB89AD437B30","latestVersionIndicator":"Yes","beginDate":"2015-04-07","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"41F89AF3-89BE-1889-E053-F662850A9BF2","beginDate":"2016-11-23","endDate":null,"createdBy":"PATELV","dateCreated":"2016-11-23","modifiedBy":"ONEDATA","dateModified":"2016-11-23","deletedIndicator":"No"},{"value":"Low-dose cytarabine","valueDescription":"Low Dose Cytarabine","ValueMeaning":{"publicId":"5806915","version":"1","preferredName":"Low Dose Cytarabine","longName":"5806915","preferredDefinition":"A minimum level or position or degree; less than normal in degree, intensity or amount.: A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.: A drug used to treat certain types of leukemia and prevent the spread of leukemia to the meninges (three thin layers of tissue that cover and protect the brain and spinal cord). It is also being studied in the treatment of other types of cancer. Cytarabine blocks tumor growth by stopping DNA synthesis. It is a type of antimetabolite.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Low","conceptCode":"C54722","definition":"A minimum level or position or degree; less than normal in degree, intensity or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4EB57027-442E-6E53-E053-F662850AEF16","latestVersionIndicator":"Yes","beginDate":"2017-05-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EB57027-4447-6E53-E053-F662850AEF16","beginDate":"2017-05-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-04","modifiedBy":"ONEDATA","dateModified":"2017-05-04","deletedIndicator":"No"},{"value":"High-dose cytarabine","valueDescription":"High Dose Cytarabine","ValueMeaning":{"publicId":"2769705","version":"1","preferredName":"High Dose Cytarabine","longName":"2769705","preferredDefinition":"High; greater than normal in degree or intensity or amount.: The amount of medicine taken, or radiation given, at one time.: An anticancer drug that belongs to the family of drugs called antimetabolites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High","conceptCode":"C25227","definition":"An elevated level or position or degree; greater than normal in degree or intensity or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5353004C-779C-0F2B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"STURGILLJ","dateCreated":"2008-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4EB57027-4451-6E53-E053-F662850AEF16","beginDate":"2017-05-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-04","modifiedBy":"ONEDATA","dateModified":"2017-05-04","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"86060C49-5DE1-0CCB-E040-BB89AD43412E","latestVersionIndicator":"Yes","beginDate":"2010-05-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-07","modifiedBy":"CAMPBELB","dateModified":"2017-05-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"INDUCTION_THERAPY_TYPE","type":"Context Short Name","context":"NRG"},{"name":"NRG","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"Induction treatment","type":"Preferred Question Text","description":"Induction treatment","url":null,"context":"CTEP"},{"name":"NRG_CRF_Text1","type":"Alternate Question Text","description":"Induction Regimen","url":null,"context":"NRG"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"860520AD-7A80-426B-E040-BB89AD434AA8","latestVersionIndicator":"Yes","beginDate":"2010-05-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-07","modifiedBy":"KRYSTKIA","dateModified":"2016-11-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}